Reasons to invest in GSK - a global healthcare company enabling people to do more, feel better and live longer.
Find out how GSK is performing with our Annual Report, Corporate Responsibility Report and financial summary.
GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma
GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate “FF”/vilanterol “VI”.
A GSK research paper published in 2010 that was found earlier this year to contain incorrect data has now been retracted by Nature Medicine.
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today the formation of the Oncology Clinical and Translational Consortium (OCTC)